Search

Additional file 4: Fig. S2. a Time from ICU admission until at least 2 PECs during ICU stay (unweighted). b Time from ICU admission until death (unweighted). C Time from ICU admission until TLD during ICU stay (unweighted). TLD: treatment limitation decision, PEC: Perceptions of Excessive Care.

Additional file 2. Master dissertation of E. Uyttersprot.

Additional file 5: Table S3. Mortality and TLDs across subgroups (unweighted results)

Variability in SF-36. In this additional file, more detailed information is given regarding variability of the SF-36 at the different time points in the 1-year cohort and 4-year cohort. Median norm-based scores with interquartile ranges on the different domains of the SF-36 over time are given in a table. (PDF 81 kb)

SF-36 assessments over time. In this additional file, evolutions in SF-36 assessments are described through figures in the 1-year cohort (47 AKI-RRT (A) and 94 non-AKI-RRT patients (B)) and in the 4-year cohort (28 AKI-RRT (C) patients and 28 non-AKI-RRT patients (D)). Percentages of patients with some or severe problems in the different domains of the SF-36 are given over the different time points: baseline, 3 months and 1 year (1-year cohort) and baseline, 3 months, 1 year and 4 years (4-year cohort). (PDF 126 kb)

Additional file 1. Definitions of collected data.

Additional file 1.

Additional file 3: Fig. S1. Flowchart study unweighted results: number of ICU’s, clinicians, perceptions and patients. PEC: Perceptions of Excessive Care. Combined endpoint: death, poor quality of life or not being at home.

EQ-5D assessments over time. In this additional file, evolutions in EQ-5D assessments are described through figures in the 1-year cohort (47 AKI-RRT (A) and 94 non-AKI-RRT patients (B)) and in the 4-year cohort (28 AKI-RRT (C) patients and 28 non-AKI-RRT patients (D)). Percentages of patients with some or severe problems in the different dimensions of the EQ-5D are given over the different time points: baseline, 3 months and 1 year (1-year cohort) and baseline, 3 months, 1 year and 4 years (4-year cohort). (PDF 111 kb)

Additional file 3. Sensitivity analysis using different BMI cut-off values.

Additional file 2. Specification of the imputation model.

Additional file 1. Details of the super learning procedure.

Further explication on statistical methods. Table S1. Center size distribution in the Trial-OH cohort and crude invasive mechanical ventilation rate by center. Table S2. Center size distribution in the HIGH trial and crude invasive mechanical ventilation rate by center. Table S3. Patient characteristics by quartiles of ICU adjusted rates of invasive mechanical ventilation- TRIALOH-Cohort (n = 703). Table S4. Center characteristics by quartiles of ICU adjusted rates of invasive mechanical ventilation-TRIAL-OH cohort (n = 17). Table S5. Patient characteristics by quartiles of ICU adjusted rates of invasive mechanical ventilation-HIGH-trial (n = 776). Table S6. Center characteristics by quartiles of ICU adjusted rates of invasive mechanical ventilation-HIGH Study (n = 31). Figure S1: Flow chart of the study. Figure S2. Adjusted probability of intubation. Figure S3. Ranking of ICUs by center effect on the mean intubation risk with and without adjustment on annual invasive mechanical ventilation rate and time from respiratory symptoms to ICU admission. Figure S4. Center effect on the effect of oxygenation strategy (High Flow Nasal cannula) on Intubation risk in the High Trial. (DOCX 13509 kb)

Additional file 1. Univariable analysis. Variables associated with hospital mortality. BMT bone marrow transplantation, CLL chronic lymphocytic leukemia, CML chronic myeloid leukemia, ED emergency department, HSCT hematopoietic stem-cell transplantation, ICU intensive care unit, MDS myelodysplastic syndrome, PS performance status, SOFA Sequential Related Organ Failure Assessment.

Additional file 2. Comparison of patient characteristics according to direct ICU admission. ALL acute lymphocytic leukemia, AML acute myeloid leukemia, BMT bone marrow transplantation, CLL chronic lymphocytic leukemia, CML chronic myeloid leukemia, ED emergency department, HSCT hematopoietic stem-cell transplantation, ICU intensive care unit, IQR interquartile range, MDS myelodysplastic syndrome, PS performance status, SOFA Sequential Related Organ Failure Assessment.

Additional file 1. Tables and figures.

Additional file 3. Loveplot. Absolute mean differences in patient characteristics before (unadjusted) and after (adjusted) matching on propensity score. BMT bone marrow transplantation, CLL chronic lymphocytic leukemia, CML chronic myeloid leukemia, HSCT hematopoietic stem-cell transplantation, ICU intensive care unit, MDS myelodysplastic syndrome, PS performance status, SOFA Sequential Related Organ Failure Assessment.

Antimicrobial use per antimicrobial class and per year. (DOC 61 kb)

Treatment duration per focus of infection. (DOC 41 kb)

Patient characteristics. (DOC 36 kb)

Additional file 1: Table S1. Comparison between BAL and No BAL groups N (%)—median [IQR 25–75]. Results were expressed as median and 25th and 75th quartiles [Q1–Q3] for quantitative data and numbers and percentages for categorical data. Marginal association between single variables and outcome was assessed by Wilcoxon rank-sum tests for quantitative variables and Fisher’s exact test or Chi-square test with Yates continuity correction for categorical variables when Fisher’s exact test was computationally impossible. CR: Complete remission; NA: Not available; PR: Partial remission; PS: Performance status; IQR: Inter-quartile range.

Additional file 1. Non exhaustive list of non invasive test that may be considered for diagnostic of acute respiratory failure.

Variability in SF-36. In this additional file, more detailed information is given regarding variability of the SF-36 at the different time points in the 1-year cohort and 4-year cohort. Median norm-based scores with interquartile ranges on the different domains of the SF-36 over time are given in a table. (PDF 81 kb)

EQ-5D assessments over time. In this additional file, evolutions in EQ-5D assessments are described through figures in the 1-year cohort (47 AKI-RRT (A) and 94 non-AKI-RRT patients (B)) and in the 4-year cohort (28 AKI-RRT (C) patients and 28 non-AKI-RRT patients (D)). Percentages of patients with some or severe problems in the different dimensions of the EQ-5D are given over the different time points: baseline, 3 months and 1 year (1-year cohort) and baseline, 3 months, 1 year and 4 years (4-year cohort). (PDF 111 kb)

Variability in EQ-5D. In this additional file, more detailed information is given regarding variability of the EQ-5D at the different time points in the 1-year cohort and 4-year cohort. Percentages and 95Â % confidence intervals of patients with some or severe problems on the respective dimensions of the EQ-5D over time are given in a table. (PDF 60 kb)

SF-36 assessments over time. In this additional file, evolutions in SF-36 assessments are described through figures in the 1-year cohort (47 AKI-RRT (A) and 94 non-AKI-RRT patients (B)) and in the 4-year cohort (28 AKI-RRT (C) patients and 28 non-AKI-RRT patients (D)). Percentages of patients with some or severe problems in the different domains of the SF-36 are given over the different time points: baseline, 3 months and 1 year (1-year cohort) and baseline, 3 months, 1 year and 4 years (4-year cohort). (PDF 126 kb)